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PREVIOUS PAPERS from these labora-
tories have reported on the efficacy of
xenogeneic tumour-directed antibodies
given in conjunction with cytotoxic agents
in suppressing growth of the EL4 lymph-
oma of C57BL/6 mice (Davies & O'Neill,
1973; Davies, 1974). This tumour was
chemically induced over 30 years ago
(Gorer, 1950) and there has recently been
criticism of the validity or relevance of
such models, especially in relation to
immunotherapy (Hewitt, 1978). The
tumour used in the experiments reported
here (SBL) is a Thy-I+ lymphoma which
arose spontaneously in a BALB/c mouse
in our inbred colo-ny in 1970 and has since
been maintained in this colony by serial
passage. The tumour is highly aggressive,
injection (i.p.) of 100 viable cells per
mouse invariably producing 100% mor-
tality. Following i.p. injection the tumour
cells disseminate, to produce a generalized
enlargement of lymphoid tissue. There is
no ascites.
The table summarizes 3 experiments in
which female BALB/c mice (10 per group)
infected i.p. with 100 viable SB1 cells
were treated on 3 successive days begin-
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ning 24 h after tumour-cell injection. Each
treatment consisted of i.p. injections of
0 3 mg cytosine arabinoside (Ara-C),
0 5 ml of rabbit anti-SB1 serum (absorbed
with packed cells from normal mouse
spleens) or both Ara-C and antiserum. In
two ofthe experiments, Ara-C significantly
increased the mean survival time. The
antiserum alone caused a modest, but not
statistically significant increase in survival
time in all 3 experiments. However, the
combination of drug and antiserum pro-
duced a highly significant inhibition of
tumour development with 40, 80 and 700o
ofanimals surviving for more than 50 days
in the 3 experiments. One of the experi-
ments (Exp. 2) had additional groups (not
shown) which were treated with normal
rabbit serum alone and with Ara-C. The
normal serum had no effect on survival
and in combination with the drug was
slightly less effective than Ara-C alone
(mean survival time 18-9 days, 3 sur-
vivors out of 10). In Exp. 3 an additional
group of mice treated with NRS alone had
a mean survival time of I 5 6 days with 2
survivors and this was not significantly
different from the control group.
TABLE. Effects of treating SB1 tumouar in vivo with Ara-C and rabbit anti-SB1 (A/S)
Exp. 2
P x N
Saline 13-5 0/10 15-2
Ara-C 17-9 0/10 < 0 05 23-3
A/S 16-1 0/10 N.S. 17-5
Ara-C+A/S 30 3 4/10 <0 01 142-9
x = Harmonic mean survival time in days.
N=Animals surviving more than 50 days.
P=From x2 values (Peto & Pike, 1973).
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These results indicate a beneficial inter-
action or synergism between antibodies
and Ara-C similar to that previously
reported for EL4. These observations
could be of some importance because
SB1, though a transplanted tumour, and
to that extent "artificial", was of spon-
taneous origin in a mouse strain with a
low tumour incidence, and is arguably
closer in nature to "spontaneous" human
tumours than are the chemically induced
tumours such as EL4.
The specificity of the antibody or anti-
bodies involved has yet to be clarified.
Absorption ofthe antisera was carried out
to eliminate toxicity (apparently asso-
ciated with haemolytic activity) and the
absorbed antisera still showed in vitro
activity against normal BALB/c lympho-
cytes. However, other antisera with
similar activity have failed to influence
the growth of SB1, so the effects recorded
here would not seem to be due to anti-
bodies against normal BALB/c tissue, but
this point should be clarified.
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